What Holosas Treats: Main Uses and Benefits

Holosas is a preparation based on the extract of Rosa Canina (Rose Hip). It is used in situations involving certain distressing symptoms and is generally applied across domains where additional symptomatic support may be needed. Its use is relevant for managing symptoms associated with functional strain and systemic imbalance, including traditional applications for biliary complaints.

---

Symptom Management Across Key Domains

Holosas is commonly used in clinical settings that involve acute or unstable symptom patterns. It is used to help manage symptoms linked to acute liver and biliary episodes, such as those seen in cholecystitis or cholangitis, and for supportive relief during episodes of systemic intoxication (e.g., drug or alcohol toxicity). It is also applicable for conditions involving recurrent or episodic manifestations related to specific nutritional deficiencies (C- and P-hypovitaminosis).

“The product supports patients in maintaining a sense of stability by helping to manage symptoms that interfere with daily comfort.”

This supportive role is relevant during phases when symptoms become more noticeable, as it may assist in easing the overall symptom load.

Quick Fact:	Used for Symptomatic Support
Holosas	Relevant in contexts where symptoms create noticeable physiological strain and temporary physiological imbalance.

Regulatory References

1. American Botanical Council’s Commission E Monograph for Rose Hip

Who Can and Cannot Use Холосас? - Official Eligibility Information

The eligibility profile for Холосас (Rose Hip Extract Syrup) is strictly defined by regulatory documents, with constraints relating to its action as a choleretic agent and its composition as a sugar-based syrup.

---

Official Eligibility Scope

Classification	Status and Population	Rationale Context
Allowed Use	Adults and Children from the age of 12 years	Established minimum age threshold for use.
Contraindicated	Biliary Tract Obstruction and Calculous Cholecystitis (Gallstones)	Prohibited due to the risk associated with stimulating bile flow.
Contraindicated	Individual Intolerance to components	Standard absolute prohibition.
Contraindicated	Exacerbations of Chronic GI Diseases	Restriction due to the naturally acidic content.
Conditional Use	Patients with Diabetes Mellitus	Caution is required due to the product’s formulation as an aqueous-sugar solution (syrup).
Not Established	Pregnancy and Lactation	Use is not recommended due to insufficient reliable data.
Not Recommended	Children under 12 years	Use is excluded by the minimum approved age threshold.

---

Summary of Eligibility Profile

The official documents define eligibility by establishing absolute contraindications, such as the prohibition in patients with biliary obstruction. Furthermore, the profile sets a clear age minimum, restricting use to those 12 years and older, and imposes conditional restrictions, notably requiring caution for diabetic patients due to the syrup formulation.

Interactions with other medicines and products

The interaction profile for Холосас is based on the documented effects of its active component, Ascorbic Acid, and its properties related to metal ion chelation and absorption, as detailed in official regulatory documents.

The regulatory profile includes strict administration timing requirements to prevent alteration of systemic drug exposure. For substances sensitive to binding by polyvalent cations, such as the medicine Eltrombopag, co-administration is subject to a mandatory time separation rule to prevent significantly decreased absorption. Similarly, Aluminum-containing Antacids must be administered at least two hours before or four hours after this product to minimize reduced efficacy and prevent increased Aluminum absorption, a concern noted for patients with renal impairment.

Exposure and Pharmacodynamic Interactions

Interacting Substance Class	Official Regulatory Outcome
Tetracycline & Quinolone Antibiotics	Decreased antibiotic exposure due to reduced gastrointestinal absorption.
Warfarin	Potential for decreased anticoagulant effect, requiring appropriate monitoring.
Oral Estrogens	Increased systemic exposure to Estrogens due to enhanced absorption.
Iron Supplements	Increased gastrointestinal absorption of non-heme iron.
Deferoxamine	Interaction is documented; caution noted for patients with cardiac impairment.
Lithium	Potential for increased plasma concentrations due to altered elimination.

The constraints detailed in official prescribing information define the use of this product by focusing on managing the risk of these alterations to plasma concentrations and pharmacodynamic effects.

Холосас is an extract derived from Rosa canina (rose hip), with a primary mechanism involving choleretic action localized to the hepatic and biliary systems. The pharmacologically active compounds, including flavonoids, polyphenols, and ascorbic acid, are absorbed and selectively accumulate within the hepatocytes.

These components promote the synthesis of bile acids by modulating enzymatic pathways within the liver. Concurrently, they stimulate the active secretion of water and electrolytes into the bile canaliculi. This dual action increases the overall volume of bile produced (hydrocholeretic effect) and facilitates its efflux from the liver and gallbladder into the duodenum. The downstream cascade involves the modulation of gastrointestinal tract motility, associated with the increased presence of bile salts and fluid in the intestinal lumen. Furthermore, various constituents act as antioxidant scavengers, interacting with and neutralizing reactive oxygen species (ROS), thereby reducing cellular oxidative stress via a non-specific radical scavenging mechanism.

The administration of Холосас syrup is conducted according to a specific pattern. The medicine is supplied as a sweet, aqueous-sugar syrup and is for oral administration.

Use Feature	Administration Detail
Route and Form	Oral intake of the syrup.
Course Duration	The standard recommended course of use typically lasts 3 to 4 weeks.
Timing	Must be taken 30 minutes before meals (on an empty stomach).

The standard single dose for adults and adolescents (aged 12 years and older) is 1 teaspoon (5 mL), administered 2 to 3 times daily. For pediatric patients: children 6 to 12 years are prescribed 1/2 teaspoon (2.5 mL) and children 3 to 6 years are prescribed 1/4 teaspoon (1.25 mL), both taken at a frequency of 2 to 3 times daily.

These parameters define the use over time. Individuals with conditions such as Diabetes Mellitus must note the sugar content inherent in the syrup formulation; a single 5 mL dose contains 0.34 Bread Units (ХЕ).

Холосас: Recent Clinical Evidence

This section summarizes research findings related to Холосас (often referred to as Holos or Rosehip extract syrup) and its primary intended uses. The primary component of this preparation is an extract derived from rosehip fruit (Rosa species), which is notably rich in Vitamin C (ascorbic acid) and other bioactive substances like carotenoids and flavonoids.

---

Therapeutic Areas Studied

Research has explored the properties of the rosehip extract in relation to liver function and bile flow, which aligns with its use in traditional medicine. Key areas of investigation include:

• Choleretic Activity: Studies have evaluated the extract's impact on bile production and secretion. Findings suggest the components may influence bile flow, a property historically associated with support for the liver and gallbladder.
• Hepatoprotective Activity: Some laboratory and in vivo studies have investigated the extract’s potential to protect liver cells against damage induced by various substances. These findings focus on the antioxidant capacity of the preparation's components.
• Vitamin Supplementation: Due to the high Vitamin C content, the extract is often studied for its systemic effects, including its role as a general tonic and its influence on the body's protective functions.

---

Clinical and Laboratory Findings

Area of Study	Observed Research Focus
Antioxidant Effect	Measured the ability of the extract's components (polyphenols, Vitamin C) to neutralize oxidative stress in laboratory models.
Liver Enzymes	Monitored changes in liver enzyme levels in animal models subjected to induced liver damage.
Bile Secretion	Quantified the rate of bile secretion in certain animal studies following administration of the extract.

The evidence base is descriptive of the pharmacological properties of the botanical components. Clinical research confirming broad therapeutic outcomes in human populations is limited, and interpretation should focus strictly on the described mechanistic and supportive properties of the extract.

Common questions about Холосас (FAQ)

Q: What is Холосас?

It is a syrup containing rose hips extract (specifically, dog-rose fruits), which is typically categorized as a plant-based agent.

---

Q: What is the main component of Холосас?

The primary active component is the aqueous extract from dog-rose (rose hips) fruit. These extracts are known to contain various compounds, including Vitamin C, flavonoids, and organic acids.

---

Q: What is Холосас generally used for?

It is traditionally used as an adjunctive agent in specific health contexts. Historically, it has been associated with promoting bile flow (a choleretic effect) and is often used to support liver and gallbladder function. Its specific use should always be clarified with a healthcare provider.

---

Q: Does Холосас treat or cure gallbladder disease?

No. Холосас is generally considered a supportive or complementary agent, not a primary treatment or cure for serious conditions like chronic gallbladder disease or cholecystitis. These conditions require specific medical intervention and diagnosis from a healthcare professional.

---

Q: Does Холосас interact with other medications?

Interactions with other medications are possible, especially for plant-based products, though information may be limited. If you are taking any prescription or non-prescription drugs, you should discuss the use of Холосас with your doctor to check for potential interactions or contraindications. Drug metabolism pathways could potentially be affected by the herb's components.

Storage and Handling Requirements

Official regulatory documents mandate specific conditions for storing Холосас syrup to preserve the stability of the active Rose Hip extract. The medicine must be stored at a temperature not exceeding 25 C and must be kept in a dark place to ensure protection from light. It is required to store the syrup in its original container, ensuring the bottle remains well-closed and tightly stoppered after use to prevent contamination. The syrup must be kept out of the sight and reach of children as a mandatory safety measure.

Disposal Instructions

Disposal of unused or expired Холосас syrup must follow official guidelines. The labeling instructs that the product be discarded strictly according to local regulatory requirements for pharmaceutical waste, which generally discourages disposal into household trash or wastewater systems.